Voyager Therapeutics(US:VYGR) Seeking Alpha·2026-03-23 06:12Core Insights - Voyager Therapeutics is focusing on 2025 as the "year of tau," with two key assets targeting tau-related conditions [2] - The company anticipates tau PET imaging data from a multiple ascending dose study by the end of the year [2] - A gene therapy asset aimed at tau knockdown, similar to BIIB080, is expected to have significant readouts in the mid-year timeframe [2] Group 1 - The first asset is a C-terminal antibody targeting tau, with imaging data expected soon [2] - The second asset is a gene therapy for tau knockdown, which is part of the company's broader strategy [2] - Voyager is introducing newly discovered blood-brain barrier (BBB) penetrant capsids into clinical trials for the first time this year [3] Group 2 - The company has two assets utilizing these capsids: the tau knockdown gene therapy and a partnered program for Friedreich's ataxia [3] - Voyager aims to establish proof of concept for the efficacy of its capsids in producing gene expression [3]